For treatment-naïve adults with HIV-1. See Full Indication.

Clinical Trials

TRIAL DESIGN

GEMINI 1 & 2 are identically designed, Phase 3 clinical trials in treatment-naïve adults

VIEW DESCRIPTION

Read more »

Virologic EFFICACY

Pooled virologic response at 48 and 96 weeks

EXPLORE RESULTS

Read more »

RESISTANCE Profile

Barrier to resistance results through 96 weeks in GEMINI 1 & 2

LEARN MORE

Read more »

BONE AND RENAL BIOMARKERS

Assessments completed through 96 weeks vs a TDF-containing regimen

SEE ASSESSMENTS

Read more »

TDF=tenofovir disoproxil fumarate.

DLLWCNT190022